PME SESSION

THURSDAY FEBRUARY 9

POINCIANA BALLROOM

12:00 PM - 12:45 PM

Alopecia Areata: What You Need to Know (Non-CME)

PRESENTED BY: Brittany G. Craiglow, MD

FRIDAY, FEBRUARY 10

POINCIANA BALLROOM

12:00 PM - 12:45 PM

A Treatment Option for Children with Uncontrolled Moderate-to-Severe Atopic Dermatitis (Non-CME)

PRESENTED BY: Shivani Patel, MD

6:00 PM - 6:30 PM

Sereneskin Oral Spore-Based Probiotics in Non-Cystic Acne Vulgaris (Non-CME)

PRESENTED BY: Thomas Bayne, DC

SPONSORED BY:

SPONSORED BY:

SPONSORED BY:

Almirall (3)

Comparison of patient and caregiver global assessment of acne severity among adolescent patients with moderate to severe non-nodular Acne Vulgaris (AV) administered sarecycline in community practices across the U.S: Analysis of PROSES study results

Hilary Baldwin,1 Adelaide Hebert,2 Andrew F. Alexis,3 James Del Rosso,4 Richard G. Fried,5 Emmy Graber,6 Julie C. Harper,7 Leon Kircik,8 Evan A Rieder,9 Linda Stein Gold,10 Siva Narayanan,11 Volker Koscielny,12 Ismail Kasujee12

Changes in acne signs and impact of acne on emotions and social functioning, among pediatric patients with moderate to severe non-nodular acne vulgaris administrated sarecycline in real-world community practices across the U.S. (PROSES study)

Hilary Baldwin,1 Adelaide Hebert,2 Andrew F. Alexis,3 James Del Rosso,4 Richard G. Fried,5 Emmy Graber,6 Julie C. Harper,7 Leon Kircik,8 Evan A Rieder,9 Linda Stein Gold,10 Siva Narayanan,11 Volker Koscielny,12 Ismail Kasujee12

Changes in social functioning, emotional functioning, and activities of daily living (ADL) among pediatric patients with moderate to severe non-nodular Acne Vulgaris (AV) administered sarecycline in real-world community practices across the U.S. (PROSES Study)

Hilary Baldwin,1 Adelaide Hebert,2 Andrew F. Alexis,3 James Del Rosso,4 Richard G. Fried,5 Emmy Graber,6 Julie C. Harper,7 Leon Kircik,8 Evan A Rieder,9 Linda Stein Gold,10 Siva Narayanan,11 Volker Koscielny,12 Ismail Kasujee12

Alphabet Health (Leo Pharma) (2)

Conjunctivitis in adolescent patients aged 12–17 with moderate-to-severe atopic dermatitis treated with tralokinumab up to week 52: results from the phase 3 ECZTRA 6 trial

Andreas Wollenberg1,2, Marjolein de Bruin-Weller3, Jacob P. Thyssen4, Lisa A. Beck5, Eric L. Simpson6, Shinichi Imafuku7, Mark Boguniewicz8, Azra Kurbasic9, Lise Soldbro9, Natacha

Strange Vest9, Petra Arlert9, Amy S. Paller10

Safety of tralokinumab in pediatric patients aged 12–17 with moderate-to-severe atopic dermatitis: results from the phase 3 ECZTRA 6 trial

Andreas Wollenberg, Michael Cork, Carsten Flohr, Anthony Bewley, Andrew Blauvelt, Chih-ho Hong, Shinichi Imafuku, Marie L.A. Schuttelaar, Eric L. Simpson, Weily Soong, Petra Arlert, Katja Lophaven, Azra Kurbasic, Lise Soldbro, Natacha Strange Vest, Amy Paller

Alphyn Biologics

Evaluation of a novel, anti-inflammatory, anti-pruritic and anti-S. aureus/MRSA topical drug in phase

2 clinical trial with favorable safety profile potentially beneficial for atopic dermatitis

Neal Koller, Alphyn Biologics

Gary Pekoe, PhD, Alphyn Biologics

CeraVe (3)

Promoting a healthy skin barrier using skin care in people with mature skin xerosis

Michael Gold MD FAAD(a) Anneke Andriessen PhD,(b) Cheryl Burgess MD FAAD,(c) Valerie Callender MD FAAD,(d) David Goldberg MD JD FAAD,(e) Firas Hougeir MD FAAD,(f) Leon Kircik MD FAAD,(g) Todd Schlesinger MD FAAD (h)

Improvement of venous dermatitis-related leg xerosis with ceramides-containing cleansers and moisturizers – an expert-based consensus

Robert S. Kirsner MD PhD(a), Anneke Andriessen PhD(b), Jason R. Hanft DPM FACFAS(c), Shasa Hu MD FAAD(a), William A. Marston MD Vascular Surgeon(d), Lee C. Ruotsi MD ABWMS

CWS-P UHM(e), Gil Yosipovitch MD FAAD(a)

Dermatology in the social media era: Building awareness on social media’s impact on adolescent skin disease and mental health

Evan E Rieder MD FAAD(a), Anneke Andriessen PhD(b), Vanessa Cutler MD(c), Mercedez E Gonzalez MD FAAD(d), Jennifer L Greenberg PsyD(e), Peter Lio MD FAAD(f), Elyse M Love MD(g), Vikash Oza(h) MD FAAD, Joyce Park MD(i), Katharine A Phillips MD(j)

Nobel Pharma (1)

Development of Consensus Statements for Treatment of Facial Angiofibroma Associated with Tuberous Sclerosis Complex

Lawrence Schachner, MD – University of Miami Miller School of Medicine. Miami, FL

Steven Sparagana, MD, FAAN – Scottish Rite for Children. Dallas, TX

Bernard Cohen, MD – Johns Hopkins School of Medicine. Baltimore, MD

Latanya Benjamin, MD, FAAD, FAAP – Florida Atlantic University, Boca Raton, FL

Mercedes E. Gonzalez, MD – Pediatric Skin Research and University of Miami Miller School of Medicine. Miami, FL

Adelaide Hebert, MD – UTHealth McGovern Medical School. Houston, TX

Lawrence Eichenfield, MD – UC San Diego School of Medicine. San Diego, FL

Elaine Siegfried, MD – SSM Health Cardinal Glennon Children’s Hospital. St. Louis, MO

Eric Beresford, PharmD, BCMAS – Nobelpharma America, LLC. Bethesda, MD